Imaging DNA damage in vivo using γH2AX-targeted immunoconjugates

Cancer Research

Volumn 71, Issue 13, 2011, Pages 4539-4549

  Cornelissen, Bart ^a   Kersemans, Veerle ^a   Darbar, Sonali ^a   Thompson, James ^a   Shah, Ketan ^a   Sleeth, Kate ^a   Hill, Mark A ^a   Vallis, Katherine A ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY CONJUGATE; BLEOMYCIN; CELL PENETRATING PEPTIDE; CYTOTOXIC AGENT; GAMMA HISTONE H2AX; HISTONE H2AX; INDIUM 111; PENTETIC ACID; PROTEIN ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; CANCER CELL; CANCER DIAGNOSIS; CARCINOGENESIS; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DNA DAMAGE; DOUBLE STRANDED DNA BREAK; DRUG RESPONSE; DRUG TARGETING; FEMALE; HUMAN; HUMAN CELL; IMAGING; IN VIVO STUDY; ISOTOPE LABELING; MOUSE; NON INVASIVE PROCEDURE; NONHUMAN; PRIORITY JOURNAL; PROTEIN LOCALIZATION; PROTEIN VARIANT; RADIATION DOSE; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TUMOR XENOGRAFT; X IRRADIATION;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES; BREAST NEOPLASMS; CARBOCYANINES; CELL LINE, TUMOR; DNA DAMAGE; DNA, NEOPLASM; FEMALE; GENE PRODUCTS, TAT; HISTONES; HUMANS; IMMUNOCONJUGATES; INDIUM RADIOISOTOPES; MICE; MICE, INBRED BALB C; MICE, NUDE; MOLECULAR SEQUENCE DATA; PENTETIC ACID; TRANSPLANTATION, HETEROLOGOUS;

EID: 79959862072     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-10-4587     Document Type: Article

References (33)

1. Halazonetis TD, Gorgoulis VG, Bartek J. An oncogene-induced DNA damage model for cancer development. Science 2008;319:1352-5. (Pubitemid 351354863)
2. Gorgoulis VG, Vassiliou LV, Karakaidos P, Zacharatos P, Kotsinas A, Liloglou T, et al. Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. Nature 2005;434:907-13. (Pubitemid 40559004)
3. Sedelnikova OA, Bonner WM. GammaH2AX in cancer cells: a potential biomarker for cancer diagnostics, prediction and recurrence. Cell Cycle 2006;5:2909-13. (Pubitemid 44953946)
4. Helleday T, Petermann E, Lundin C, Hodgson B, Sharma RA. DNA repair pathways as targets for cancer therapy. Nat Rev Cancer 2008;8:193-204. (Pubitemid 351301852)
5. Qvarnstrom OF, Simonsson M, Johansson KA, Nyman J, Turesson I. DNA double strand break quantification in skin biopsies. Radiother Oncol 2004;72:311-7. (Pubitemid 39265385)
6. Olive PL. Detection of DNA damage in individual cells by analysis of histone H2AX phosphorylation. Methods Cell Biol 2004;75:355-73.
7. Blankenberg FG, Vanderheyden JL, Strauss HW, Tait JF. Radiolabeling of HYNIC-Annexin V with technetium-99m for in vivo imaging of apoptosis. Nat Protoc 2006;1:108-10.
8. Edgington LE, Berger AB, Blum G, Albrow VE, Paulick MG, Lineberry N, et al. Noninvasive optical imaging of apoptosis by caspase-targeted activity-based probes. Nat Med 2009;15:967-73.
9. Boersma HH, Kietselaer BL, Stolk LM, Bennaghmouch A, Hofstra L, Narula J, et al. Past, present, and future of Annexin A5: from protein discovery to clinical applications. J Nucl Med 2005;46:2035-50. (Pubitemid 46657451)
10. Banath JP, Klokov D, MacPhail SH, Banuelos CA, Olive PL. Residual gammaH2AX foci as an indication of lethal DNA lesions. BMC Cancer 2010;10:4.
11. Banath JP, Olive PL. Expression of phosphorylated histone H2AX as a surrogate of cell killing by drugs that create DNA double-strand breaks. Cancer Res 2003;63:4347-50. (Pubitemid 36951002)
12. Bonner WM, Redon CE, Dickey JS, Nakamura AJ, Sedelnikova OA, Solier S, et al. GammaH2AX and cancer. Nat Rev Cancer 2008;8:957-67.
13. Dickey JS, Redon CE, Nakamura AJ, Baird BJ, Sedelnikova OA, Bonner WM. H2AX: functional roles and potential applications. Chromosoma 2009;118:683-92.
14. Heitz F, Morris MC, Divita G. Twenty years of cell-penetrating peptides: from molecular mechanisms to therapeutics. Br J Pharmacol 2009;157:195-206.
15. Costantini DL, Hu M, Reilly RM. Peptide motifs for insertion of radiolabeled biomolecules into cells and routing to the nucleus for cancer imaging or radiotherapeutic applications. Cancer Biother Radiopharm 2008;23:3-24. (Pubitemid 351304218)
16. Hu M, Chen P, Wang J, Scollard DA, Vallis KA, Reilly RM. 123I-labeled HIV-1 tat peptide radioimmunoconjugates are imported into the nucleus of human breast cancer cells and functionally interact in vitro and in vivo with the cyclin-dependent kinase inhibitor, p21(WAF-1/Cip-1). Eur J Nucl Med Mol Imaging 2007;34:368-77. (Pubitemid 46295344)
17. Cornelissen B, Kersemans V, McLarty K, Tran L, Vallis KA, Reilly RM. In vivo monitoring of intranuclear p27(kip1) protein expression in breast cancer cells during trastuzumab (Herceptin) therapy. Nucl Med Biol 2009;36:811-9.
18. Hnatowich DJ, Rusckowski M, Brill AB, Siebecker DA, Misra H, Mardirossian G, et al. Pharmacokinetics in patients of an anti-carcinoembryonic antigen antibody radiolabeled with indium-111 using a novel diethylenetriamine pentaacetic acid chelator. Cancer Res 1990;50:7272-8.
19. 123I-labeled HIV-1 tat peptide immunoconjugates in BT-474 human breast cancer cells. Nucl Med Biol 2007;34:37-46.
20. Hill MA, Stevens DL, Kadhim M, Blake-James M, Mill AJ, Goodhead DT. Experimental techniques for studying bystander effects in vitro by high and low-LET ionising radiation. Radiat Prot Dosimetry 2006;122:260-5. (Pubitemid 47090461)
21. 111In-DTPA-hEGF. J Nucl Med 2008;49:1353-61.
22. Bartkova J, Horejsi Z, Koed K, Kramer A, Tort F, Zieger K, et al. DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature 2005;434:864-70. (Pubitemid 40558993)
23. Oka K, Tanaka T, Enoki T, Yoshimura K, Ohshima M, Kubo M, et al. DNA damage signaling is activated during cancer progression in human colorectal carcinoma. Cancer Biol Ther 2010;9:246-52.
24. Wasco MJ, Pu RT, Yu L, Su L, Ma L. Expression of gamma-H2AX in melanocytic lesions. Hum Pathol 2008;39:1614-20.
25. Rube CE, Grudzenski S, Kuhne M, Dong X, Rief N, Lobrich M, et al. DNA double-strand break repair of blood lymphocytes and normal tissues analysed in a preclinical mouse model: implications for radiosensitivity testing. Clin Cancer Res 2008;14:6546-55.
26. Banuelos CA, Banath JP, Kim JY, Aquino-Parsons C, Olive PL. gammaH2AX expression in tumors exposed to cisplatin and fractionated irradiation. Clin Cancer Res 2009;15:3344-53.
27. Lord CJ, Ashworth A. Bringing DNA repair in tumors into focus. Clin Cancer Res 2009;15:3241-3.
28. Nakamura A, Sedelnikova OA, Redon C, Pilch DR, Sinogeeva NI, Shroff R, et al. Techniques for gamma-H2AX detection. Methods Enzymol 2006;409:236-50.
29. Kinner A, Wu W, Staudt C, Iliakis G. Gamma-H2AX in recognition and signaling of DNA double-strand breaks in the context of chromatin. Nucleic Acids Res 2008;36:5678-94.
30. Rogakou EP, Pilch DR, Orr AH, Ivanova VS, Bonner WM. DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139. J Biol Chem 1998;273:5858-68. (Pubitemid 28124064)
31. Brunner AH, Hinterholzer S, Riss P, Heinze G, Weiss K, Brustmann H. Expression of gamma-H2AX in endometrial carcinomas: an immunohistochemical study with p53. Gynecol Oncol 2010;121:206-11.
32. 57Cobleomycin. Eur J Nucl Med 1983;8:535-40.
33. Torchilin VP. Passive and active drug targeting: drug delivery to tumors as an example. Handb Exp Pharmacol 2010:3-53.